Morbidity and Mortality Outcomes of Dupilumab for Cutaneous Immune-Related Adverse Events
This cohort study evaluates morbidity and mortality outcomes associated with dupilumab treatment in patients with cutaneous immune-related adverse events.
Authors
- Shayan Owji (ORCID: https://orcid.org/0000-0002-5632-3824)
- Brandon Block (ORCID: https://orcid.org/0000-0003-2802-6969)
- T. Marron
- Nicholas Gulati
- Jaanvi Mehta
- Dan Feng
Institutions
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1001/jamaoncol.2025.6092
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00